Signals
AstraZeneca’s potential $1.5B insitro deal puts AI on the hardest question in cardiometabolic R&D
AstraZeneca has partnered with AI therapeutics company insitro to discover new targets and medicines for MASH and cardiomyopathies, paying $40 million upfront with up to $1.46 billion tied to future development and commercial milestones.
Erectile Dysfunction Is Already a Cardiovascular Risk Marker. New Data Link It to Glaucoma Too
Retatrutide Isn’t Approved. Online, ‘Reta’ Is Already a Weight-Loss Brand
Cardiology Has Long Said “Eat Whole Grains.” New Evidence Asks How Much
Novo’s $1.4B Orbis Deal Bets on a New Route to Oral Cardiometabolic Drugs
Can Belgium Turn Routine GP Data Into Cardiovascular Prevention?
Not All Fat Is Obesity: Lipedema Trial Challenges Weight-Centred Care
The healthcare AI race is shifting from smarter models to safer deployment
GLP-1s Are Winning on Weight. Muscle Is Becoming the Next Clinical Question
Britain Wants an AI-Enabled NHS. Scaling Innovation Is Still the Bottleneck
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.